Signs of an ‘October Vaccine Surprise’ Alarm Career Scientists
A growing number of prominent health leaders fear that President Donald Trump will legally autorize a vaccine before election day, running roughshod over the usual regulatory process.
vaccine
COVID Vaccine Trials Move Fast But They're Slow To Recruit Black Volunteers
So far, participation by minority volunteers in coronavirus trials has increased only slightly compared with the usually low levels in other clinical trials.
NIH ‘Very Concerned’ About Serious Side Effect in Coronavirus Vaccine Trial
The Food and Drug Administration is weighing whether to resume a coronavirus vaccine trial that was halted when a volunteer suffered spinal cord damage as federal health officials launch an investigation.
Fauci Says COVID Vaccine Trials Could End Early If Results Are Overwhelming
The nation's top infectious disease expert says If a monitoring board gave the green light, vaccine manufacturers would be obligated to end their trials early and make the shots available.
Rather Than Give Away Its COVID Vaccine, Oxford Makes a Deal With Drugmaker
Oxford University has signed an exclusive deal with AstraZeneca that gives the pharmaceutical giant sole rights with no guarantee of low prices.
Kaiser Permanente In Portland Joins COVID-19 Vaccine Trial
The nonprofit will be testing a new drug developed by Pfizer and BioNTech that produced a strong immune response in early trials.
Test Sites Quickly Attract Thousands for COVID-19 Vaccine Study
During the next two months, vaccine makers hope to recruit 60,000 Americans, including in Oregon, to roll up their sleeves to test two vaccines.
Fauci Unfazed as Scientists Rely on Unproven Methods to Create COVID Vaccines
With millions of lives on the line, researchers have been working at an unprecedented pace to develop a COVID-19 vaccine.
A Coronavirus Vaccine: Where Does It Stand?
Scientists say they see steady progress and are expressing cautious optimism that a vaccine could be ready by spring.
Analysis: How A COVID-19 Vaccine Could Cost Americans Dearly
Given the prevailing business-centric model of American drug pricing, a COVID-19 vaccine could be budget breaking, perhaps making it unavailable to many.
Pages
